Drug Trial Radar · NCT00194519
Herpes Simplex Virus Type 2 (HSV-2) Suppression to Prevent HIV Transmission
Last checked: Nov 19, 2026Latest source record: Oct 12, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
3,408
Actual
Start
Nov 2004
Primary completion
Nov 2009
Study completion Mar 2010
Sponsor
- Lead sponsor
- University of WashingtonAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Bill and Melinda Gates Foundation
- First posted
- Sep 19, 2005
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The University of Washington has received funding to conduct a proof-of-concept trial to assess the impact of suppression of genital herpes on HIV infectiousness. This study (the Partners in Prevention Study) will enroll HIV discordant heterosexual couples in which the HIV-infected partner is co-infected with herpes simplex virus type 2 (HSV-2) to test the efficacy of twice daily (bid) acyclovir (400 mg) given to the HIV-infected partner to prevent transmission to his/her HIV negative partner(s). This randomized, double-blind, placebo-controlled proof-of-concept trial will provide evidence for the efficacy of HSV-2 suppression with daily acyclovir on HIV transmission among HIV-discordant couples among whom the HIV-positive partner is also HSV-2 seropositive with CD4 \>250. The researchers hypothesis is that, by decreasing the frequency and amount of genital HIV shedding, standard doses of daily acyclovir 400 mg bid will reduce the rate of HIV transmission by 50% in HIV-discordant couples among whom the HIV-infected partner is HSV-2 positive. Under the study protocol version 4.1.1, 3000 HIV-discordant heterosexual couples in which the HIV-positive partner is HSV-2 positive and has a CD4 count \>250 will be recruited; participants will be followed for up to 2 years. A 4% per year HIV incidence in the placebo arm is assumed. The first study site began enrolling participants on 17 November 2005. As of September 2006, 14 sites in Eastern and Southern Africa had participated in recruiting the 2300 HIV-discordant couples enrolled to date.
Conditions
- HIV Infection
- Herpes Simplex, Genital
- Sexually Transmitted Diseases
Interventions
Generic acyclovirDrug
400 mg twice-daily oral
PlaceboDrug
twice-daily oral
Primary outcomes
What the sponsor says the trial is designed to measure.
- Sequence-verified HIV-transmission from index to partner participantTime frame: March 2009
Locations
13 sites in 7 countries. Site status is shown where the registry gives one.
Botswana-Harvard Partnership
Gabarone, Botswana
Moi University - Indiana University
Eldoret, Kenya
Kemri - Ucsf
Kisumu, Kenya
University of Nairobi
Nairobi, Kenya
Partners Study Thika Site
Thika, Kenya
Projet San Francisco-Emory University
Kigali, Rwanda
University of Cape Town
Cape Town, South Africa
Perinatal HIV Research Unit, University of Witswatersrand
Johannesburg, South Africa
Reproductive Health and HIV Research Unit
Johannesburg, South Africa
Kilimanjaro Christian Medical College-Harvard University
Moshi, Tanzania
Mulago Hospital - IDI
Kampala, Uganda
Zambia-Emory HIV Research Project
Lusaka, Zambia
Zambia-Emory HIV Research Project
Ndola/Kitwe, Zambia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.